p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG.
The tumor suppressor protein p53 plays a key role in regulation of negative cellular growth in response to EGCG. To further explore the role of p53 signaling and elucidate the molecular mechanism, we employed colon cancer HCT116 cell line and its derivatives in which a specific transcriptional target of p53 is knocked down by homologous recombination. Cells expressing p53 and p21 accumulate in G1 upon treatment with EGCG. In contrast, same cells lacking p21 traverse through the cell cycle and eventually undergo apoptosis as revealed by TUNEL staining. Treatment with EGCG leads to induction of p53, p21 and PUMA in p21 wild-type, and p53 and PUMA in p21(-/-) cells. Ablation of p53 by RNAi protects p21(-/-) cells, thus indicating a p53-dependent apoptosis by EGCG. Furthermore, analysis of cells lacking PUMA or Bax with or without p21 but with p53 reveals that all the cells expressing p53 and p21 survived after EGCG treatment. More interestingly, cells lacking both PUMA and p21 survived ECGC treatment whereas those lacking p21 and Bax did not. Taken together, our results present a novel concept wherein p21-dependent growth arrest pre-empts and protects cells from otherwise, in its absence, apoptosis which is mediated by activation of pro-apoptotic protein PUMA. Furthermore, we find that p53-dependent activation of PUMA in response to EGCG directly leads to apoptosis with out requiring Bax as is the case in response to agents that induce DNA damage. p21, thus can be used as a molecular switch for therapeutic intervention of colon cancer.
Thakur
Vijay S
VS
Department of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA.
Ruhul Amin
A R M
AR
Paul
Rajib K
RK
Gupta
Kalpana
K
Hastak
Kedar
K
Agarwal
Mukesh K
MK
Jackson
Mark W
MW
Wald
David N
DN
Mukhtar
Hasan
H
Agarwal
Munna L
ML
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000172:deficiency / Q000235:genetics* / Q000502:physiology; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism*; D004249:DNA Damage; D016158:Genes, p53 / Q000187:drug effects; D045325:HCT116 Cells / Q000473:pathology / Q000502:physiology*; D006801:Humans; D011518:Proto-Oncogene Proteins / Q000172:deficiency / Q000235:genetics* / Q000502:physiology; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
D016588:Anticarcinogenic Agents; D051017:Apoptosis Regulatory Proteins; C438378:BBC3 protein, human; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D002392:Catechin; C045651:epigallocatechin gallate
Biol Pharm Bull. 2008 Jan;31(1):79-84
18175946
Cancer Biol Ther. 2003 Sep-Oct;2(5):477-90
14614312
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
17380161
J Cell Sci. 2005 May 1;118(Pt 9):1821-32
15827088
Cell Cycle. 2007 May 2;6(9):1006-10
17457049
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16278-83
17050687
Mol Cell. 2006 Feb 3;21(3):307-15
16455486
Cancer Res. 2007 Jun 15;67(12):5617-21
17575126
J Biol Chem. 2002 Oct 4;277(40):37949-54
12151395
Am J Clin Nutr. 2000 Jun;71(6 Suppl):1698S-702S; discussion 1703S-4S
10837321
Clin Cancer Res. 2004 Jul 15;10(14):4865-73
15269163
J Clin Oncol. 2009 Jun 1;27(16):2712-25
19414669
Cancer Biol Ther. 2007 Jun;6(6):965-73
17534142
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5419-24
17369354
Clin Cancer Res. 2005 Apr 1;11(7):2735-46
15814656
Int J Biochem Cell Biol. 2006;38(10):1637-41
16600663
Br J Cancer. 2001 Mar 23;84(6):844-50
11259102
Biochem Pharmacol. 2003 Nov 1;66(9):1769-78
14563487
Cancer. 2001 Feb 15;91(4):822-32
11241252
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1931-6
12574499
Cancer Res. 2005 Mar 1;65(5):1647-54
15753358
Mol Cell Biochem. 2001 Feb;218(1-2):147-55
11330830
Oncogene. 2003 Jul 31;22(31):4851-9
12894226
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6314-9
18434539
Clin Cancer Res. 2001 Aug;7(8):2168-81
11489790
J Biol Chem. 1998 Jan 2;273(1):1-4
9417035
J Nutr. 2003 Oct;133(10):3268S-3274S
14519825
FASEB J. 2005 May;19(7):789-91
15764647
Anticancer Drugs. 1991 Jun;2(3):233-45
1802017
Nature. 2000 Nov 16;408(6810):307-10
11099028
Cancer Res. 2007 Apr 15;67(8):3862-70
17440101